Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 7/20 | 0.37 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104880 | 0.88 | METTL3 (0.48) | METTL3EGFRCSF1RLMNAKLKB1 | |
| SCHEMBL4207612 | 0.81 | METTL3 (0.50) | METTL3EGFRCSF1RLMNAHTR1D | |
| SCHEMBL1104898 | 0.80 | METTL3 (0.49) | METTL3EGFRSGMS2CSF1RLMNA | |
| SCHEMBL1104891 | 0.80 | METTL3 (0.56) | METTL3CSF1R | |
| SCHEMBL16482241 | 0.79 | AHR (0.34) | METTL3SGMS2LMNAKLKB1HSP90AA1 | |
| SCHEMBL4209881 | 0.79 | METTL3 (0.48) | METTL3CSF1RLMNA | |
| Hydrochloric Acid SCHEMBL4211289 | 0.79 | METTL3 (0.55) | METTL3CSF1R | |
| SCHEMBL1104896 | 0.76 | METTL3 (0.47) | METTL3EGFRCSF1RLMNA | |
| SCHEMBL13927561 | 0.75 | METTL3 (0.48) | METTL3EGFRCSF1RLMNAHTR1D | |
| SCHEMBL13927523 | 0.74 | METTL3 (0.48) | METTL3EGFRCSF1RLMNAHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906529-B9 | A NEW PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR | ZENTIVA KS (CZ) | 2017-03-15 | — | — | EP | disclosed |
| EP-2190804-B1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES INC (US) | 2015-11-18 | — | — | EP | disclosed |
| EP-2069280-B1 | Process and intermediates for preparing HIV integrase inhibitors | GILEAD SCIENCES INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8796459-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796459-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8759525-B2 | Process and intermediates for preparing integrase inhibitors | Gilhead Sciences, Inc. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2644587-A2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20130253200-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253200-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8440831-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20100292480-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292480-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC (US) | 2010-11-18 | — | — | US | disclosed |
| US-7825252-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825252-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090099366-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099366-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009036161-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20080125594-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125594-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2008033836-A2 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099366-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885EGFR 4014/4885SGMS2 4432/4885 |
| US-20080125594-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885EGFR 4014/4885SGMS2 4432/4885 |
| US-20100292480-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885EGFR 4014/4885SGMS2 4432/4885 |
| US-20130253200-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885EGFR 4014/4885SGMS2 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.